Aerodynamic Design of the RAE 2822 in Transonic Viscous Flow: Single- and Multi-Objective Optimization Studies

This paper addresses a benchmark aerodynamic design problem proposed by the AIAA Aerodynamic Design Optimization Discussion Group: Drag minimization of the RAE 2822 in transonic viscous flow at a fixed lift coefficient with constraints on the pitching moment coefficient and the cross-sectional area. The single-objective optimization (SOO) problem is solved using surrogate-based optimization (SBO) with the surrogates constructed through output space mapping and variable-resolution Reynolds-Averaged Navier-Stokes computational fluid dynamics models. Improving the implementation of our search algorithms enabled us to obtain the SOO optimal design four times faster than in our prior work in terms of CPU time. To explore the design space in the vicinity of the SOO optimal design, the problem is recast as a multi-objective optimization (MOO) one by treating the drag and pitching moment coefficients as the objectives while fulfilling the given constraints on the lift coefficient and the cross-sectional area. The MOO algorithm yields the Pareto front of the two conflicting objective functions in close proximity of the design obtained by the SOO formulation in the feasible and infeasible space of the original SOO problem

Aerodynamic Design of a Rectangular Wing in Subsonic Inviscid Flow by Surrogate-Based Optimization

The paper presents results of aerodynamic design of a rectangular wing in subsonic inviscid flow using surrogate-based local and global search algorithms. The aerodynamic design problem is formulated in Benchmark Cases 3 and 6 developed by the AIAA Applied Aerodynamics Discussion Group. Both involve lift-constrained drag minimization at a Mach number of 0.5 with relatively low lift coefficients (0.2625 and 0.375) with several nonlinear constraints and a small number design variables (up to 15). In this work, the local search is performed using variable-fidelity modelling and output space mapping, whereas the global search is performed using approximation-based surrogates. The paper presents the details of the computational modelling, shape parameterization, optimization algorithms, and results for each benchmark case. The approaches yield comparable results for Benchmark Case 3. Only the local search algorithm is applied to Benchmark Case 6. The results indicate the multimodality of that design case

Terpenoid Esters Are the Major Constituents From Leaf Lipid Droplets of Camellia sinensis

Lipid droplets (LDs) have been widely found from diverse species and exhibit diverse functions. It remains unexplored what potential roles they played in tea. To address this question, we analyzed the chemical composition and the dynamic changes of cytosolic LDs during leaf growth and diurnal cycle. Using TopFluor cholesterol and Nile Red staining we demonstrated that cytosolic LDs were heterogeneous in tea tree (Camellia sinensis cv. Tieguanyin); the size and number of LDs increased with leaf growth. Compositional analysis showed that terpenoid esters and diacylglycerol are the major components of cytosolic LDs. The contents of total sterol esters (SEs) and β-amyrin esters increased with leaf expansion and growth; individual SE also showed diurnal changes. Our data suggest that cytosolic LDs from tea tree leave mainly serve as storage site for free sterols and triterpenoids in the form of esters. Cytosolic LDs were not the major contributors to the aroma quality of made tea

The centre cannot (always) hold:Examining pathways towards energy system de-centralisation

This is the final version. Available on open access from Elsevier via the DOI in this record'Energy decentralisation' means many things to many people. Among the confusion of definitions and practices that may be characterised as decentralisation, three broad causal narratives are commonly (implicitly or explicitly) invoked. These narratives imply that the process of decentralisation: i) will result in appropriate changes to rules and institutions, ii) will be more democratic and iii) is directly and causally linked to energy system decarbonisation. The principal aim of this paper is to critically examine these narratives. By conceptualising energy decentralisation as a distinct class of sociotechnical transition pathway, we present a comparative analysis of energy decentralisation in Cornwall, South West UK, the French island of Ushant and the National Electricity Market in Australia. We show that, while energy decentralisation is often strongly correlated with institutional change, increasing citizen agency in the energy system, and enhanced environmental performance, these trends cannot be assumed as given. Indeed, some decentralisation pathways may entrench incumbent actors' interests or block rapid decarbonisation. In particular, we show how institutional context is a key determinant of the link between energy decentralisation and normative goals such as democratisation and decarbonisation. While institutional theory suggests that changes in rules and institutions are often incremental and path-dependent, the dense legal and regulatory arrangements that develop around the electricity sector seem particularly resistant to adaptive change. Consequently, policymakers seeking to pursue normative goals such as democratisation or decarbonisation through energy decentralisation need to look beyond technology towards the rules, norms and laws that constitute the energy governance system.Engineering and Physical Sciences Research Council (EPSRC)European Structural and Investment FundINTERREG V FC

CXCL12 expression by healthy and malignant ovarian epithelial cells

<p>Abstract</p> <p>Background</p> <p>CXCL12 has been widely reported to play a biologically relevant role in tumor growth and spread. In epithelial ovarian cancer (EOC), CXCL12 enhances tumor angiogenesis and contributes to the immunosuppressive network. However, its prognostic significance remains unclear. We thus compared CXCL12 status in healthy and malignant ovaries, to assess its prognostic value.</p> <p>Methods</p> <p>Immunohistochemistry was used to analyze CXCL12 expression in the reproductive tracts, including the ovaries and fallopian tubes, of healthy women, in benign and borderline epithelial tumors, and in a series of 183 tumor specimens from patients with advanced primary EOC enrolled in a multicenter prospective clinical trial of paclitaxel/carboplatin/gemcitabine-based chemotherapy (GINECO study). Univariate COX model analysis was performed to assess the prognostic value of clinical and biological variables. Kaplan-Meier methods were used to generate progression-free and overall survival curves.</p> <p>Results</p> <p>Epithelial cells from the surface of the ovary and the fallopian tubes stained positive for CXCL12, whereas the follicles within the ovary did not. Epithelial cells in benign, borderline and malignant tumors also expressed CXCL12. In EOC specimens, CXCL12 immunoreactivity was observed mostly in epithelial tumor cells. The intensity of the signal obtained ranged from strong in 86 cases (47%) to absent in 18 cases (<10%). This uneven distribution of CXCL12 did not reflect the morphological heterogeneity of EOC. CXCL12 expression levels were not correlated with any of the clinical parameters currently used to determine EOC prognosis or with HER2 status. They also had no impact on progression-free or overall survival.</p> <p>Conclusion</p> <p>Our findings highlight the previously unappreciated constitutive expression of CXCL12 on healthy epithelia of the ovary surface and fallopian tubes, indicating that EOC may originate from either of these epithelia. We reveal that CXCL12 production by malignant epithelial cells precedes tumorigenesis and we confirm in a large cohort of patients with advanced EOC that CXCL12 expression level in EOC is not a valuable prognostic factor in itself.</p> <p>Trial Registration</p> <p>ClinicalTrials.gov: <a href="http://www.clinicaltrials.gov/ct2/show/NCT00052468">NCT00052468</a></p

Nothing New in the (North) East? Interpreting the Rhetoric and Reality of Japanese Corporate Governance

Japan finally seems to be pulling itself out of its lost decade (and a half) of economic stagnation. Some grudgingly or triumphantly attribute this to micro-economic reforms, freeing up arthritic markets, although there is also evidence that macro-economic policy failures have been a major cause of poor performance since the 1990s. Many point to overlapping transformations in corporate governance, broadly defined to cover relationships among managers and employees as well as between firms and outside shareholders, creditors, and other stakeholders. These relationships are in flux, with moves arguably favouring shareholders and more market-driven control mechanisms. It has certainly been a found decade for law reform in Japan, particularly in corporate law, with a plethora of legislative amendments commencing around 1993 and culminating in the enactment of a consolidated Company Law in 2005. This modernisation project, particularly since 2001, is reportedly aimed at (i) securing better corporate governance, (ii) bringing the law into line with a highly-developed information society, (iii) liberalising fundraising measures, (iv) bringing corporate law into line with the internationalization of corporate activity, and (v) modernizing terms and consolidating corporate law. Because the suite of revisions has moved away from strict mandatory rules set out originally in Japan\u27s Commercial Code of 1899, modeled primarily on German law, another growing perception is that Japanese corporate law and practice is or will soon be converging significantly on US models. However, assessments remain divided as to whether these moves in corporate governance and capitalism more generally in Japan amount to a new paradigm or regime shift . Focusing primarily on quite influential commentary in English, Part I of this paper outlines two pairs of views. It concludes that the most plausible assessment is of significant but gradual transformation towards a more market-driven approach, evident also in other advanced political economies. Drawing more generally from these often virulently divided views, Part II sets out five ways forward through the proliferating literature and source material on corporate governance in Japan. Particular care must be taken in: (i) selecting the temporal timeframe, (ii) selecting countries to compare, (iii) balancing black-letter law and broader socio-economic context, (iv) reflecting on and disclosing normative preferences, and (v) giving weight to processes as well as outcomes, when assessing change in Japan - and any other country\u27s governance system. Part III ends with a call for further research particularly on law- and policy-producing processes, rather than mainly outcomes. It also outlines the usefulness of this analytical framework for analysing the broader field of Corporate Social Responsibility, now emerging as the next major area of debate and transformation in Japan - as elsewhere

Fucoidan Can Function as an Adjuvant In Vivo to Enhance Dendritic Cell Maturation and Function and Promote Antigen-Specific T Cell Immune Responses

Fucoidan, a sulfated polysaccharide purified from brown algae, has a variety of immune-modulation effects, including promoting antigen uptake and enhancing anti-viral and anti-tumor effects. However, the effect of fucoidan in vivo, especially its adjuvant effect on in vivo anti-tumor immune responses, was not fully investigated. In this study, we investigated the effect of fucoidan on the function of spleen dendritic cells (DCs) and its adjuvant effect in vivo. Systemic administration of fucoidan induced up-regulation of CD40, CD80 and CD86 expression and production of IL-6, IL-12 and TNF-α in spleen cDCs. Fucoidan also promoted the generation of IFN-γ-producing Th1 and Tc1 cells in an IL-12-dependent manner. When used as an adjuvant in vivo with ovalbumin (OVA) antigen, fucoidan promoted OVA-specific antibody production and primed IFN-γ production in OVA-specific T cells. Moreover, fucoidan enhanced OVA-induced up-regulation of MHC class I and II on spleen cDCs and strongly prompted the proliferation of OVA-specific CD4 and CD8 T cells. Finally, OVA immunization with fucoidan as adjuvant protected mice from the challenge with B16-OVA tumor cells. Taken together, these results suggest that fucoidan can function as an adjuvant to induce Th1 immune response and CTL activation, which may be useful in tumor vaccine development